Isomorphic Labs
Venture Round in 2025
Isomorphic Labs is a biotechnology company that leverages artificial intelligence to revolutionize drug discovery. It develops advanced platforms to analyze and interpret complex biological data, aiding in the identification of potential drug candidates. The company partners with pharmaceutical firms to enhance the efficiency and precision of drug development by offering services such as data analysis, modeling, and simulation.
Allara Health
Series B in 2025
Allara Health is a healthcare provider specializing in virtual care for women facing complex, chronic health conditions, particularly polycystic ovary syndrome (PCOS). The company offers a comprehensive program that connects patients with medical providers and registered dietitians through virtual appointments. Allara's services include holistic care, diagnostic testing, and prescriptions, along with personalized guidance on dietary and lifestyle changes. By leveraging technology, the platform enables women to efficiently manage their health, allowing for improved tracking and treatment of their conditions.
Metsera is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for obesity and metabolic conditions. The company focuses on advancing a variety of treatment options, including both oral and injectable therapies, specifically targeting incretin, non-incretin, and combination approaches. By integrating proprietary health technology tools, Metsera aims to provide personalized care that meets the evolving demands of weight loss treatment. Its commitment to addressing multiple therapeutic targets positions the company to significantly impact the future of obesity management and related metabolic diseases.
Ubie
Corporate Round in 2024
Ubie, Inc. is a Tokyo-based company founded in 2017 that specializes in developing artificial intelligence-powered healthcare solutions. Its core offering is an AI-driven symptom checker that generates personalized evaluation reports for patients. Through a brief questionnaire that customizes its inquiries based on factors such as biological sex, age, medical history, and lifestyle choices, the tool aims to assist users in understanding potential causes of their symptoms. In addition to providing patients with detailed reports, Ubie also supplies physicians with patient summaries and predictive diagnoses to enhance clinical decision-making.
Nym Health Inc., established in 2017 and headquartered in Boston, Massachusetts, specializes in medical coding technology for healthcare facilities. Its core product, Nym, is an autonomous coding solution that streamlines revenue cycle management. Nym reduces denials and operational expenses by directly billing and accurately assigning medical charge codes from patient charts, improving payment cycles and audit-readiness. It identifies relevant clinical aspects, assigns codes, and provides an audit trail explaining its coding decisions. With a research and development center in Tel Aviv-Yafo, Israel, Nym enables healthcare providers to enhance coding quality, lower costs, and focus more on patient care.
PGxAI is an AI-powered pharmacogenetics platform that redefines precision medicine using proprietary algorithms and real-world data. Partnered with InterSystems, the largest patient data holder globally, and leveraging advanced tools like VectorSearch and GenAI, PGxAI accesses extensive real-world data to solve drug selection, dosage personalization, and identification of clinically relevant drug-drug interactions.
AccuLine is a digital healthcare company dedicated to preventing heart attacks and saving lives through early detection of coronary artery disease (CAD). The company has developed CORA, a non-invasive examination technology that provides a smart, accurate, and user-friendly alternative to traditional stress tests. This innovative platform delivers swift and cost-effective assessments, allowing healthcare providers to identify CAD more effectively and efficiently. By replacing outdated and labor-intensive methods, AccuLine aims to enhance patient outcomes and revolutionize the way heart disease is diagnosed and managed.
Metsera is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for obesity and metabolic conditions. The company focuses on advancing a variety of treatment options, including both oral and injectable therapies, specifically targeting incretin, non-incretin, and combination approaches. By integrating proprietary health technology tools, Metsera aims to provide personalized care that meets the evolving demands of weight loss treatment. Its commitment to addressing multiple therapeutic targets positions the company to significantly impact the future of obesity management and related metabolic diseases.
Oula Health
Series B in 2024
Oula Health, Inc. is a maternity care provider based in Brooklyn, New York, established in 2019. The company focuses on redesigning maternity care by integrating obstetrics and midwifery to create a personalized and evidence-based experience for expecting families. Oula operates clinics and offers home-based prenatal care services, aiming to set a new standard for pregnancy care that harmonizes modern medical practices with a compassionate approach. Through its innovative model, Oula Health seeks to enhance the overall maternity care experience for its clients.
Signos is a health technology company focused on addressing the obesity epidemic by promoting healthy habits and stabilizing glucose levels through innovative solutions. The company offers a weight loss application that leverages continuous glucose monitoring in conjunction with an AI-enhanced platform. This combination provides users with real-time data and personalized recommendations for meals and exercises tailored to their unique metabolic responses. By enabling individuals to better understand their body's reactions to food, Signos aims to facilitate effective weight loss and foster sustainable health improvements. With a significant portion of the American population facing weight-related challenges, Signos presents a modern approach to support users on their journey towards healthier living.
Allara Health
Series A in 2023
Allara Health is a healthcare provider specializing in virtual care for women facing complex, chronic health conditions, particularly polycystic ovary syndrome (PCOS). The company offers a comprehensive program that connects patients with medical providers and registered dietitians through virtual appointments. Allara's services include holistic care, diagnostic testing, and prescriptions, along with personalized guidance on dietary and lifestyle changes. By leveraging technology, the platform enables women to efficiently manage their health, allowing for improved tracking and treatment of their conditions.
RAD-AID International
Grant in 2023
RAD-AID International is dedicated to improve radiology services in the developing world and poor areas.
Causal Foundry
Grant in 2023
Causal Foundry is a personalization to solve the greatest challenges in healthcare and medicine.
IDinsight with Reach Digital Health
Grant in 2023
IDinsight with Reach Digital Health developed a natural language-enabled question-and-answer service for pregnant moms that delivers responses to questions as well as important health information.
Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. It is an innovative company that is dedicated to transforming the clinical research ecosystem. Their mission is to create a more accessible and equitable healthcare system by developing a platform that enables patients from diverse backgrounds to participate in clinical trials. Clinical trials are essential for testing and developing new drugs, therapies, and medical devices, but historically, they have been plagued by inefficiencies, barriers to access, and inequities in patient representation. Paradigm aims to solve these challenges by creating a platform that uses technology and data-driven insights to streamline the clinical trial process, making it more efficient, cost-effective, and inclusive. The Paradigm platform is designed to facilitate seamless communication and collaboration among all stakeholders involved in clinical research, including patients, healthcare providers, pharmaceutical companies, and regulatory agencies. By leveraging technology such as AI, machine learning, and predictive analytics, Paradigm can identify and match eligible patients to clinical trials, streamline the recruitment and enrollment process, and provide real-time data insights to all stakeholders. Overall, Paradigm's innovative approach to clinical research has the potential to revolutionize the healthcare industry by improving patient outcomes, reducing healthcare costs, and accelerating the development of new treatments and therapies.
Osmo
Venture Round in 2023
Osmo is a company that develops an artificial intelligence platform designed to give computers a sense of smell. By combining advanced AI with olfactory science, Osmo addresses significant challenges in the fragrance industry while also aiming to enhance human health and well-being. The company creates aroma molecules for a variety of products, including perfumes, shampoos, lotions, and candles. Additionally, Osmo's technology has the potential to detect diseases earlier and track pandemics, thereby improving consumer experience and overall wellness. Through its innovative approach, Osmo seeks to transform the way scent is integrated into everyday life and contribute positively to public health.
Kindbody
Venture Round in 2022
Kindbody is a comprehensive fertility clinic network and family-building benefits provider that offers a wide range of services aimed at improving access to healthcare for women. The company provides both virtual and in-person care, including fertility assessments, education, preservation, genetic testing, in vitro fertilization (IVF), donor and surrogacy services, and adoption. By partnering with employers, Kindbody delivers financial, medical, and emotional support to employees pursuing parenthood. The company serves more than 100 employers, covering over 2.4 million lives, while also providing direct fertility care through its network of signature clinics, mobile clinics, and partner clinics across the country. With a focus on affordability and accessibility, Kindbody employs modern technology to deliver holistic health and fertility services.
Medallion
Series C in 2022
Medallion is a San Francisco-based company founded in 2020 by Derek Lo, specializing in a network management platform tailored for the healthcare industry. The company offers an all-in-one solution for licensing, credentialing, and payer enrollment, aimed at simplifying the often cumbersome processes associated with healthcare paperwork. Its platform provides features such as primary source verification, continuing medical education tracking, and document management, enabling healthcare providers and telemedicine companies to minimize time spent on administrative tasks and focus more on patient care.
Syrona Health
Seed Round in 2022
Syrona Health is a digital health company focused on personalized gynecological care throughout various life stages, including menstrual health, fertility, parenthood, and menopause. It offers a virtual health support platform that integrates software and hardware to enhance gynecological health outcomes. The company's solutions address conditions such as endometriosis, polycystic ovary syndrome (PCOS), and gynecological cancers, enabling women to monitor their health independently. Syrona Health also provides at-home clinical testing and online counseling, allowing women to manage their gynecological health proactively without relying on lengthy clinic visits for diagnostics.
Viz.ai, Inc. specializes in healthcare imaging software designed to enhance stroke care through the use of artificial intelligence. The company's flagship technology synchronizes treatment by reducing delays in patient care, enabling rapid identification of large vessel occlusion (LVO) strokes using advanced deep learning algorithms. Key offerings include Viz LVO, which alerts on-call stroke teams based on CT angiogram images, and Viz CTP, which analyzes CT perfusion images and generates critical parametric data. Additionally, Viz HUB facilitates communication among clinical teams to coordinate care efficiently, while Viz VIEW allows healthcare professionals to view imaging data on mobile devices. Founded in 2016 and headquartered in San Francisco, the company aims to transform healthcare delivery by improving the speed and accessibility of treatment for stroke patients.
Brightline
Series C in 2022
Brightline, Inc. is a pediatric behavioral health care provider that focuses on supporting children and their families through innovative technology and integrated care. Established in 2019 and headquartered in Palo Alto, California, Brightline offers a range of services including behavioral therapy, psychiatry, medication support, speech-language therapy, and occupational therapy. The company emphasizes virtual behavioral health services and a collaborative care team to address the diverse needs of children at various developmental stages. Originally named Emilio Health, Inc., the company rebranded to Brightline in May 2020, reflecting its commitment to delivering accessible and comprehensive behavioral health solutions.
Elly
Venture Round in 2022
Elly Health Inc. specializes in developing audio companion software designed for patients, healthcare providers, and organizations. Founded in 2019 and headquartered in Los Angeles, California, the company offers Elly, an innovative empathetic audio companion specifically tailored for individuals managing chronic diseases. This technology aims to motivate and support patients by connecting them with expert advice and community contributions, thereby enhancing their healthcare experience. Elly Health Inc. stands out as a pioneer in the realm of empathetic digital health solutions.
DNAnexus, Inc. is a cloud-based provider of genome informatics and data management tools, primarily serving enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and the integration of genomic data with clinical information. Its suite of products includes MOSAIC Microbiome for collaborative research on the human microbiome, DNAnexus Apollo for clinico-genomic data exploration, and DNAnexus Titan for data analysis. Additionally, the DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration, while the Clinico-Genomic Data Solution addresses the need for disease-specific datasets through partnerships with healthcare providers. The company has established itself as a key player in the biopharmaceutical, diagnostic, and academic research sectors, enabling clients to tackle complex challenges in human health with enhanced security and scalability. DNAnexus also maintains a strategic alliance with WuXi NextCODE Genomics and has locations in San Francisco, London, and Prague.
Signos is a health technology company focused on addressing the obesity epidemic by promoting healthy habits and stabilizing glucose levels through innovative solutions. The company offers a weight loss application that leverages continuous glucose monitoring in conjunction with an AI-enhanced platform. This combination provides users with real-time data and personalized recommendations for meals and exercises tailored to their unique metabolic responses. By enabling individuals to better understand their body's reactions to food, Signos aims to facilitate effective weight loss and foster sustainable health improvements. With a significant portion of the American population facing weight-related challenges, Signos presents a modern approach to support users on their journey towards healthier living.
Cambridge Epigenetix
Series D in 2021
Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, specializing in epigenetic tools that aim to transform medical diagnostics. Founded in 2012 as a spin-out from the University of Cambridge, the company is pioneering the clinical applications of epigenetics, particularly through its innovative TrueMethyl technology. This includes oxidative bisulfite sequencing, which allows for the precise sequencing of hydroxymethyl cytosine and methylcytosine at single-base resolution. Cambridge Epigenetix offers a range of products, such as TrueMethyl 6 and TrueMethyl 24 kits, designed for the quantitative measurement and analysis of these critical epigenetic markers. The company’s research highlights the significance of 5-hydroxymethylcytosine as a biomarker for various diseases, including colorectal cancer, and aims to simplify diagnostic processes to a simple blood draw. The firm collaborates with third-party vendors and sells its products directly to business customers both in the UK and internationally.
Sprinter Health
Series A in 2021
Sprinter Health is a mobile healthcare company that provides on-demand services by sending full-time nurses and phlebotomists to patients' homes. The company aims to improve access to preventive care through modern house calls, enhancing the patient experience and satisfaction. By utilizing a cost-effective hybrid care model, Sprinter Health connects patients with essential healthcare services, allowing them to receive quality care in the comfort of their own homes. This approach not only improves health outcomes but also addresses the growing demand for convenient and accessible healthcare solutions.
Ultromics
Series B in 2021
Ultromics Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in developing advanced echocardiography software aimed at enhancing the diagnosis of coronary heart disease. By leveraging artificial intelligence, the company has created highly accurate diagnostic tools that improve the identification of coronary artery disease, achieving diagnostic accuracy improvements of over 90%. Ultromics' technology processes complex data from electrocardiograms, empowering healthcare providers to make informed clinical decisions and ultimately enhancing patient care in cardiology.
Nym Health Inc., established in 2017 and headquartered in Boston, Massachusetts, specializes in medical coding technology for healthcare facilities. Its core product, Nym, is an autonomous coding solution that streamlines revenue cycle management. Nym reduces denials and operational expenses by directly billing and accurately assigning medical charge codes from patient charts, improving payment cycles and audit-readiness. It identifies relevant clinical aspects, assigns codes, and provides an audit trail explaining its coding decisions. With a research and development center in Tel Aviv-Yafo, Israel, Nym enables healthcare providers to enhance coding quality, lower costs, and focus more on patient care.
CourMed
Seed Round in 2021
CourMed is a private client health services company that specializes in delivering healthcare products and services directly to clients' homes, offices, or other locations. The company offers a unique concierge service model, which emphasizes personalized and convenient health and wellness solutions. Clients can choose between two membership options: Purple, which ensures concierge visits within 3-5 days, and Platinum, which guarantees same day or next day visits. CourMed's offerings include in-home consultations, patient advocacy, regenerative therapies, and DNA-personalized supplements. Additionally, the company utilizes software to track delivery processes, ensuring proof of delivery, confirmation signatures, and product images for clients. This innovative approach allows CourMed to provide accessible emergency services and a high level of customer satisfaction.
Kindbody is a comprehensive fertility clinic network and family-building benefits provider that offers a wide range of services aimed at improving access to healthcare for women. The company provides both virtual and in-person care, including fertility assessments, education, preservation, genetic testing, in vitro fertilization (IVF), donor and surrogacy services, and adoption. By partnering with employers, Kindbody delivers financial, medical, and emotional support to employees pursuing parenthood. The company serves more than 100 employers, covering over 2.4 million lives, while also providing direct fertility care through its network of signature clinics, mobile clinics, and partner clinics across the country. With a focus on affordability and accessibility, Kindbody employs modern technology to deliver holistic health and fertility services.
Brightline
Series B in 2021
Brightline, Inc. is a pediatric behavioral health care provider that focuses on supporting children and their families through innovative technology and integrated care. Established in 2019 and headquartered in Palo Alto, California, Brightline offers a range of services including behavioral therapy, psychiatry, medication support, speech-language therapy, and occupational therapy. The company emphasizes virtual behavioral health services and a collaborative care team to address the diverse needs of children at various developmental stages. Originally named Emilio Health, Inc., the company rebranded to Brightline in May 2020, reflecting its commitment to delivering accessible and comprehensive behavioral health solutions.
Vera Therapeutics
Series C in 2021
Vera Therapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2016 and formerly known as Trucode Gene Repair, Inc. The company focuses on developing innovative biologic therapeutics with the potential to transform treatment for patients suffering from serious immunological diseases and genetic disorders. Its lead product candidate, atacicept, is a fusion protein administered as a subcutaneous injection once weekly, designed to inhibit factors that stimulate the production of autoantibodies associated with autoimmune diseases. Additionally, Vera Therapeutics is utilizing gene-editing technology aimed at addressing conditions such as sickle cell disease and cystic fibrosis, striving to enhance gene detection and regulation for improved patient outcomes.
Tempus, established in 2015 and based in Chicago, Illinois, is a technology company specializing in precision medicine. It develops a comprehensive library of molecular and clinical data, along with an operating system that makes this information accessible and useful for patients, physicians, and researchers. Tempus offers services such as genomic sequencing, clinical data restructuring, and biological modeling, enabling real-time data-driven decisions for personalized patient care and facilitating the discovery of optimized therapeutic options.
Tempus
Debt Financing in 2020
Tempus, established in 2015 and based in Chicago, Illinois, is a technology company specializing in precision medicine. It develops a comprehensive library of molecular and clinical data, along with an operating system that makes this information accessible and useful for patients, physicians, and researchers. Tempus offers services such as genomic sequencing, clinical data restructuring, and biological modeling, enabling real-time data-driven decisions for personalized patient care and facilitating the discovery of optimized therapeutic options.
Elly
Venture Round in 2020
Elly Health Inc. specializes in developing audio companion software designed for patients, healthcare providers, and organizations. Founded in 2019 and headquartered in Los Angeles, California, the company offers Elly, an innovative empathetic audio companion specifically tailored for individuals managing chronic diseases. This technology aims to motivate and support patients by connecting them with expert advice and community contributions, thereby enhancing their healthcare experience. Elly Health Inc. stands out as a pioneer in the realm of empathetic digital health solutions.
Nym Health Inc., established in 2017 and headquartered in Boston, Massachusetts, specializes in medical coding technology for healthcare facilities. Its core product, Nym, is an autonomous coding solution that streamlines revenue cycle management. Nym reduces denials and operational expenses by directly billing and accurately assigning medical charge codes from patient charts, improving payment cycles and audit-readiness. It identifies relevant clinical aspects, assigns codes, and provides an audit trail explaining its coding decisions. With a research and development center in Tel Aviv-Yafo, Israel, Nym enables healthcare providers to enhance coding quality, lower costs, and focus more on patient care.
Arkangel AI is a technology company that provides a no-code platform designed for healthcare organizations to harness the capabilities of artificial intelligence. Its platform enables the building, deployment, and management of machine learning algorithms at scale, focusing on the detection of preventable diseases. By generating detection results that are faster, more accurate, and cost-effective, Arkangel AI helps users identify the stage of health issues efficiently. The company's mission is to promote equitable health conditions globally, empowering individuals to live free from preventable diseases. Through its innovative solutions, Arkangel AI aims to enhance healthcare outcomes and accessibility for all.
Kindbody is a comprehensive fertility clinic network and family-building benefits provider that offers a wide range of services aimed at improving access to healthcare for women. The company provides both virtual and in-person care, including fertility assessments, education, preservation, genetic testing, in vitro fertilization (IVF), donor and surrogacy services, and adoption. By partnering with employers, Kindbody delivers financial, medical, and emotional support to employees pursuing parenthood. The company serves more than 100 employers, covering over 2.4 million lives, while also providing direct fertility care through its network of signature clinics, mobile clinics, and partner clinics across the country. With a focus on affordability and accessibility, Kindbody employs modern technology to deliver holistic health and fertility services.
PatientPing
Series C in 2020
PatientPing, Inc. is a health technology company that has developed a national care coordination network aimed at enhancing communication among healthcare providers. Founded in 2013 and headquartered in Boston, Massachusetts, the company offers real-time notifications and care guidelines to various healthcare professionals, including physicians, nurses, case managers, and care coordinators. This network spans hospitals, emergency departments, accountable care organizations, physician practices, skilled nursing facilities, home health agencies, and payers. PatientPing's platform includes a tool called Spotlights, which leverages real-time data to analyze utilization and performance trends in patient care. By improving information sharing among care teams, PatientPing facilitates higher quality, cost-effective care, ultimately aiming to enhance patient outcomes and experiences. The company also maintains a strategic partnership with MedAllies, Inc. and operates as a subsidiary of SVB Leerink Holdings LLC.
DNAnexus, Inc. is a cloud-based provider of genome informatics and data management tools, primarily serving enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and the integration of genomic data with clinical information. Its suite of products includes MOSAIC Microbiome for collaborative research on the human microbiome, DNAnexus Apollo for clinico-genomic data exploration, and DNAnexus Titan for data analysis. Additionally, the DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration, while the Clinico-Genomic Data Solution addresses the need for disease-specific datasets through partnerships with healthcare providers. The company has established itself as a key player in the biopharmaceutical, diagnostic, and academic research sectors, enabling clients to tackle complex challenges in human health with enhanced security and scalability. DNAnexus also maintains a strategic alliance with WuXi NextCODE Genomics and has locations in San Francisco, London, and Prague.
Element Science
Series C in 2020
Element Science, Inc. is a medical device and digital health company focused on developing innovative solutions for high-risk cardiovascular patients. Founded in 2011 and headquartered in San Francisco, California, the company specializes in a patch-based wearable cardioverter defibrillator (WCD) designed to monitor patients' heart activity and mitigate the risks associated with sudden cardiac death. Element Science integrates advanced machine learning algorithms with human-centered design principles and stringent electromechanical medical device standards to create a proprietary wearable digital platform. This platform aims to provide continuous protection for patients with heart disease, addressing critical health needs as they transition from hospital care to daily life.
Kindbody is a comprehensive fertility clinic network and family-building benefits provider that offers a wide range of services aimed at improving access to healthcare for women. The company provides both virtual and in-person care, including fertility assessments, education, preservation, genetic testing, in vitro fertilization (IVF), donor and surrogacy services, and adoption. By partnering with employers, Kindbody delivers financial, medical, and emotional support to employees pursuing parenthood. The company serves more than 100 employers, covering over 2.4 million lives, while also providing direct fertility care through its network of signature clinics, mobile clinics, and partner clinics across the country. With a focus on affordability and accessibility, Kindbody employs modern technology to deliver holistic health and fertility services.
Kindbody is a comprehensive fertility clinic network and family-building benefits provider that offers a wide range of services aimed at improving access to healthcare for women. The company provides both virtual and in-person care, including fertility assessments, education, preservation, genetic testing, in vitro fertilization (IVF), donor and surrogacy services, and adoption. By partnering with employers, Kindbody delivers financial, medical, and emotional support to employees pursuing parenthood. The company serves more than 100 employers, covering over 2.4 million lives, while also providing direct fertility care through its network of signature clinics, mobile clinics, and partner clinics across the country. With a focus on affordability and accessibility, Kindbody employs modern technology to deliver holistic health and fertility services.
Fitbit
Acquisition in 2019
Fitbit is a company focused on promoting healthier lifestyles through its digital health and fitness devices. It develops the Fitbit Tracker, a compact wireless wearable sensor that automatically monitors various aspects of a user's activities, including calories burned, sleep quality, steps taken, and distance traveled. This device continuously collects data while worn throughout the day, which is then wirelessly uploaded to a dedicated website. Users can access their information to track progress toward personal health goals, engage with a motivational interface, and share achievements with friends, family, and co-workers. Additionally, the platform allows users to manually log nutrition, weight, and other health metrics, providing a comprehensive overview of their well-being. By automating health data collection and offering an engaging user experience, Fitbit aims to simplify the journey toward a healthier lifestyle.
Viz.ai, Inc. specializes in healthcare imaging software designed to enhance stroke care through the use of artificial intelligence. The company's flagship technology synchronizes treatment by reducing delays in patient care, enabling rapid identification of large vessel occlusion (LVO) strokes using advanced deep learning algorithms. Key offerings include Viz LVO, which alerts on-call stroke teams based on CT angiogram images, and Viz CTP, which analyzes CT perfusion images and generates critical parametric data. Additionally, Viz HUB facilitates communication among clinical teams to coordinate care efficiently, while Viz VIEW allows healthcare professionals to view imaging data on mobile devices. Founded in 2016 and headquartered in San Francisco, the company aims to transform healthcare delivery by improving the speed and accessibility of treatment for stroke patients.
Vera Therapeutics
Venture Round in 2019
Vera Therapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2016 and formerly known as Trucode Gene Repair, Inc. The company focuses on developing innovative biologic therapeutics with the potential to transform treatment for patients suffering from serious immunological diseases and genetic disorders. Its lead product candidate, atacicept, is a fusion protein administered as a subcutaneous injection once weekly, designed to inhibit factors that stimulate the production of autoantibodies associated with autoimmune diseases. Additionally, Vera Therapeutics is utilizing gene-editing technology aimed at addressing conditions such as sickle cell disease and cystic fibrosis, striving to enhance gene detection and regulation for improved patient outcomes.
Westmead Applied Research Centre
Grant in 2019
Embracing innovative research to improve patient and population health The University of Sydney,
Collective Health
Series E in 2019
Collective Health is a health benefits platform that integrates various medical, dental, vision, and pharmacy services into a cohesive solution aimed at simplifying healthcare for employees and their families. The company’s cloud-based platform streamlines the administration of health plans through a single portal, offering clear guidance, live concierge support, and digital tools for managing care. By reducing the administrative burden associated with health benefits, Collective Health enhances the member experience and aids organizations in controlling costs while improving health outcomes. Headquartered in San Francisco, California, the company also has offices in Chicago, Illinois, and Lehi, Utah.
CTRL-Labs
Venture Round in 2019
CTRL-Labs Corporation, founded in 2015 and based in New York City, specializes in non-invasive neural interface technology that transforms human-machine interaction. The company has developed CTRL-kit, a wristband equipped with sensors that captures and translates neural signals into control inputs for digital devices. This innovative platform addresses key challenges in virtual and augmented reality, robotics, productivity, and clinical research by allowing developers to integrate neural control into their applications through an SDK and API. CTRL-Labs aims to establish a new paradigm in human-computer collaboration, positioning itself for future consumer adoption of technology that enables seamless interaction between users and machines. Through its scientific initiatives and partnerships, CTRL-Labs is paving the way for advanced applications of its neural interface technology across various industries.
DNAnexus, Inc. is a cloud-based provider of genome informatics and data management tools, primarily serving enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and the integration of genomic data with clinical information. Its suite of products includes MOSAIC Microbiome for collaborative research on the human microbiome, DNAnexus Apollo for clinico-genomic data exploration, and DNAnexus Titan for data analysis. Additionally, the DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration, while the Clinico-Genomic Data Solution addresses the need for disease-specific datasets through partnerships with healthcare providers. The company has established itself as a key player in the biopharmaceutical, diagnostic, and academic research sectors, enabling clients to tackle complex challenges in human health with enhanced security and scalability. DNAnexus also maintains a strategic alliance with WuXi NextCODE Genomics and has locations in San Francisco, London, and Prague.
HelpMum is a digital social enterprise operating in Africa, focused on reducing maternal and infant mortality. It offers a mobile platform that includes a vaccination tracker and AI-driven reminders, helping parents adhere to immunization schedules. Additionally, HelpMum distributes clean birth kits to underserved areas, further supporting maternal and infant health. The company leverages mobile technology and low-cost innovation to tackle these critical health challenges.
Imagen enables Primary Care providers to become technology-enabled multispecialty practices, powering a successful transition from fee-for-service to value-based care. Its comprehensive platform includes in-office diagnostic testing, diagnostic interpretations powered by proprietary FDA-cleared machine learning software, and virtual specialist consults. Its platform empowers Primary Care providers to achieve healthcare’s quadruple aim of increasing quality, lowering costs, and improving the patient and provider experience.
Cambridge Epigenetix
Series C in 2018
Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, specializing in epigenetic tools that aim to transform medical diagnostics. Founded in 2012 as a spin-out from the University of Cambridge, the company is pioneering the clinical applications of epigenetics, particularly through its innovative TrueMethyl technology. This includes oxidative bisulfite sequencing, which allows for the precise sequencing of hydroxymethyl cytosine and methylcytosine at single-base resolution. Cambridge Epigenetix offers a range of products, such as TrueMethyl 6 and TrueMethyl 24 kits, designed for the quantitative measurement and analysis of these critical epigenetic markers. The company’s research highlights the significance of 5-hydroxymethylcytosine as a biomarker for various diseases, including colorectal cancer, and aims to simplify diagnostic processes to a simple blood draw. The firm collaborates with third-party vendors and sells its products directly to business customers both in the UK and internationally.
Viz.ai, Inc. specializes in healthcare imaging software designed to enhance stroke care through the use of artificial intelligence. The company's flagship technology synchronizes treatment by reducing delays in patient care, enabling rapid identification of large vessel occlusion (LVO) strokes using advanced deep learning algorithms. Key offerings include Viz LVO, which alerts on-call stroke teams based on CT angiogram images, and Viz CTP, which analyzes CT perfusion images and generates critical parametric data. Additionally, Viz HUB facilitates communication among clinical teams to coordinate care efficiently, while Viz VIEW allows healthcare professionals to view imaging data on mobile devices. Founded in 2016 and headquartered in San Francisco, the company aims to transform healthcare delivery by improving the speed and accessibility of treatment for stroke patients.
CTRL-Labs
Series B in 2018
CTRL-Labs Corporation, founded in 2015 and based in New York City, specializes in non-invasive neural interface technology that transforms human-machine interaction. The company has developed CTRL-kit, a wristband equipped with sensors that captures and translates neural signals into control inputs for digital devices. This innovative platform addresses key challenges in virtual and augmented reality, robotics, productivity, and clinical research by allowing developers to integrate neural control into their applications through an SDK and API. CTRL-Labs aims to establish a new paradigm in human-computer collaboration, positioning itself for future consumer adoption of technology that enables seamless interaction between users and machines. Through its scientific initiatives and partnerships, CTRL-Labs is paving the way for advanced applications of its neural interface technology across various industries.
IDEAYA Biosciences
Series B in 2018
IDEAYA Biosciences, Inc., established in 2015 and headquartered in South San Francisco, California, specializes in oncology-focused precision medicine. The company discovers and develops targeted therapeutics for patient populations selected through molecular diagnostics. Its lead product candidate, IDE196, is a protein kinase C inhibitor currently in Phase 1/2 clinical trials for genetically-defined cancers with GNAQ or GNA11 gene mutations. IDEAYA's preclinical pipeline includes programs targeting MAT2A, Pol-theta, PARG, and WRN in various solid tumors. The company collaborates with institutions like Cancer Research UK and Pfizer Inc., and has partnerships with industry leaders such as GlaxoSmithKline plc.
Collective Health
Series D in 2018
Collective Health is a health benefits platform that integrates various medical, dental, vision, and pharmacy services into a cohesive solution aimed at simplifying healthcare for employees and their families. The company’s cloud-based platform streamlines the administration of health plans through a single portal, offering clear guidance, live concierge support, and digital tools for managing care. By reducing the administrative burden associated with health benefits, Collective Health enhances the member experience and aids organizations in controlling costs while improving health outcomes. Headquartered in San Francisco, California, the company also has offices in Chicago, Illinois, and Lehi, Utah.
DNAnexus, Inc. is a cloud-based provider of genome informatics and data management tools, primarily serving enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and the integration of genomic data with clinical information. Its suite of products includes MOSAIC Microbiome for collaborative research on the human microbiome, DNAnexus Apollo for clinico-genomic data exploration, and DNAnexus Titan for data analysis. Additionally, the DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration, while the Clinico-Genomic Data Solution addresses the need for disease-specific datasets through partnerships with healthcare providers. The company has established itself as a key player in the biopharmaceutical, diagnostic, and academic research sectors, enabling clients to tackle complex challenges in human health with enhanced security and scalability. DNAnexus also maintains a strategic alliance with WuXi NextCODE Genomics and has locations in San Francisco, London, and Prague.
Rodin Therapeutics
Series C in 2017
Rodin Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapeutics for cognitive disorders through epigenetic modulation. Founded in 2013, the company leverages insights into key epigenetic regulators of central nervous system (CNS) function to create innovative treatments. Rodin's approach involves harnessing the power of epigenetic regulation, particularly through the modulation of HDAC complexes, to restore synaptic function and enhance neuronal health in patients suffering from degenerative brain diseases. The company is supported by a team experienced in CNS drug development and has access to advanced structural biology capabilities. Rodin Therapeutics operates as a subsidiary of Alkermes Inc.
Senosis Health
Acquisition in 2017
Senosis Health is a startup focused on mobile health monitoring. The company develops applications that utilize the capabilities of smartphones, such as the accelerometer, microphone, flash, and camera, to measure, diagnose, and manage diseases. Their solutions include monitoring lung health and hemoglobin counts, providing users with accessible healthcare tools directly on their mobile devices.
ZappRx is a digital health company based in Boston, Massachusetts, founded in 2012. It specializes in providing a cloud-based platform that streamlines the process of ordering specialty medications for healthcare providers, specialty pharmacies, and biopharma companies. The platform facilitates secure digital interactions among providers, pharmacists, and payers, reducing reliance on traditional methods like faxes and phone calls. By automating prescription management and prior authorization processes, ZappRx enhances efficiency in collecting and maintaining necessary information for specialty prescribing. This includes details such as pharmacy information, payer requirements, and clinical history. The company's platform is utilized across various medical fields, including pulmonary, cardiology, and gastroenterology.
Element Science
Series B in 2016
Element Science, Inc. is a medical device and digital health company focused on developing innovative solutions for high-risk cardiovascular patients. Founded in 2011 and headquartered in San Francisco, California, the company specializes in a patch-based wearable cardioverter defibrillator (WCD) designed to monitor patients' heart activity and mitigate the risks associated with sudden cardiac death. Element Science integrates advanced machine learning algorithms with human-centered design principles and stringent electromechanical medical device standards to create a proprietary wearable digital platform. This platform aims to provide continuous protection for patients with heart disease, addressing critical health needs as they transition from hospital care to daily life.
Juicero, Inc. is a company based in San Francisco, California, that specializes in developing cold-press juicing systems for producing raw and organic fruit and vegetable juices. Founded in 2013, Juicero offers an innovative home juicing system that allows users to create fresh juice with minimal effort, using a machine that combines advanced cold-pressing technology with an application designed to enhance the juicing experience. This application connects to the juicer, providing users with information about the sourcing of their ingredients, nutritional content, and managing juice pack deliveries. Juicero's product line includes various juice packs, featuring combinations like sweet greens, spicy greens, and root vegetables, aimed at encouraging healthier consumption of fresh produce.
Cambridge Epigenetix
Series B in 2016
Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, specializing in epigenetic tools that aim to transform medical diagnostics. Founded in 2012 as a spin-out from the University of Cambridge, the company is pioneering the clinical applications of epigenetics, particularly through its innovative TrueMethyl technology. This includes oxidative bisulfite sequencing, which allows for the precise sequencing of hydroxymethyl cytosine and methylcytosine at single-base resolution. Cambridge Epigenetix offers a range of products, such as TrueMethyl 6 and TrueMethyl 24 kits, designed for the quantitative measurement and analysis of these critical epigenetic markers. The company’s research highlights the significance of 5-hydroxymethylcytosine as a biomarker for various diseases, including colorectal cancer, and aims to simplify diagnostic processes to a simple blood draw. The firm collaborates with third-party vendors and sells its products directly to business customers both in the UK and internationally.
PatientPing
Series A in 2015
PatientPing, Inc. is a health technology company that has developed a national care coordination network aimed at enhancing communication among healthcare providers. Founded in 2013 and headquartered in Boston, Massachusetts, the company offers real-time notifications and care guidelines to various healthcare professionals, including physicians, nurses, case managers, and care coordinators. This network spans hospitals, emergency departments, accountable care organizations, physician practices, skilled nursing facilities, home health agencies, and payers. PatientPing's platform includes a tool called Spotlights, which leverages real-time data to analyze utilization and performance trends in patient care. By improving information sharing among care teams, PatientPing facilitates higher quality, cost-effective care, ultimately aiming to enhance patient outcomes and experiences. The company also maintains a strategic partnership with MedAllies, Inc. and operates as a subsidiary of SVB Leerink Holdings LLC.
Collective Health
Series C in 2015
Collective Health is a health benefits platform that integrates various medical, dental, vision, and pharmacy services into a cohesive solution aimed at simplifying healthcare for employees and their families. The company’s cloud-based platform streamlines the administration of health plans through a single portal, offering clear guidance, live concierge support, and digital tools for managing care. By reducing the administrative burden associated with health benefits, Collective Health enhances the member experience and aids organizations in controlling costs while improving health outcomes. Headquartered in San Francisco, California, the company also has offices in Chicago, Illinois, and Lehi, Utah.
Metabiota
Series A in 2015
Metabiota, Inc. is a San Francisco-based company founded in 2008 that specializes in assessing and investigating infectious disease threats. The company employs pathogen discovery, disease detection, and threat characterization to provide data, analytics, and strategies aimed at reducing and preventing infectious disease outbreaks. Metabiota’s platform allows local authorities and organizations to prepare mitigation strategies and manage complex infectious disease risks effectively. By offering surveillance, recognition, and diagnosis of microbial threats, Metabiota plays a critical role in helping governments and corporations track and respond to global health challenges. Through its strategic global presence and partnerships, the company is dedicated to mitigating the impacts of epidemic threats.
Hello Heart
Venture Round in 2015
Hello Heart Inc., established in 2013 and headquartered in Redwood City, California, specializes in developing digital health solutions. Its flagship product is Hello Heart, a mobile application designed to empower individuals to manage their heart health effectively. The app enables users to track their blood pressure and weight, providing real-time personalized tips based on clinical guidelines. Employers can also utilize this platform to proactively manage employee health risks associated with high blood pressure, fostering behavior change and preventing serious health issues.
Flatiron Health
Series B in 2014
Flatiron Health, Inc. is a healthcare technology company dedicated to enhancing cancer research and patient care through advanced data integration and analytics. The firm develops OncologyCloud, a comprehensive platform that consolidates disparate healthcare information systems to provide insights into patient populations. This platform enables cancer care providers and life sciences companies to analyze treatment patterns, monitor adherence to clinical guidelines, and facilitate real-time patient matching to clinical trials. Additionally, Flatiron offers OncoCloud, a software solution for community oncology practices, and tools like Flatiron Assist and OncoEMR, which support clinical decision-making and compliance with oncology care models. Established in 2012 and headquartered in New York, Flatiron Health collaborates with over 280 community cancer practices, prominent academic research centers, and leading oncology companies, positioning itself as a key player in the oncology data landscape. The company operates as a subsidiary of Roche Holding AG.
Metabiota
Seed Round in 2014
Metabiota, Inc. is a San Francisco-based company founded in 2008 that specializes in assessing and investigating infectious disease threats. The company employs pathogen discovery, disease detection, and threat characterization to provide data, analytics, and strategies aimed at reducing and preventing infectious disease outbreaks. Metabiota’s platform allows local authorities and organizations to prepare mitigation strategies and manage complex infectious disease risks effectively. By offering surveillance, recognition, and diagnosis of microbial threats, Metabiota plays a critical role in helping governments and corporations track and respond to global health challenges. Through its strategic global presence and partnerships, the company is dedicated to mitigating the impacts of epidemic threats.
Element Science
Series A in 2014
Element Science, Inc. is a medical device and digital health company focused on developing innovative solutions for high-risk cardiovascular patients. Founded in 2011 and headquartered in San Francisco, California, the company specializes in a patch-based wearable cardioverter defibrillator (WCD) designed to monitor patients' heart activity and mitigate the risks associated with sudden cardiac death. Element Science integrates advanced machine learning algorithms with human-centered design principles and stringent electromechanical medical device standards to create a proprietary wearable digital platform. This platform aims to provide continuous protection for patients with heart disease, addressing critical health needs as they transition from hospital care to daily life.
DNAnexus, Inc. is a cloud-based provider of genome informatics and data management tools, primarily serving enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and the integration of genomic data with clinical information. Its suite of products includes MOSAIC Microbiome for collaborative research on the human microbiome, DNAnexus Apollo for clinico-genomic data exploration, and DNAnexus Titan for data analysis. Additionally, the DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration, while the Clinico-Genomic Data Solution addresses the need for disease-specific datasets through partnerships with healthcare providers. The company has established itself as a key player in the biopharmaceutical, diagnostic, and academic research sectors, enabling clients to tackle complex challenges in human health with enhanced security and scalability. DNAnexus also maintains a strategic alliance with WuXi NextCODE Genomics and has locations in San Francisco, London, and Prague.
Collective Health
Series A in 2014
Collective Health is a health benefits platform that integrates various medical, dental, vision, and pharmacy services into a cohesive solution aimed at simplifying healthcare for employees and their families. The company’s cloud-based platform streamlines the administration of health plans through a single portal, offering clear guidance, live concierge support, and digital tools for managing care. By reducing the administrative burden associated with health benefits, Collective Health enhances the member experience and aids organizations in controlling costs while improving health outcomes. Headquartered in San Francisco, California, the company also has offices in Chicago, Illinois, and Lehi, Utah.
SynapDx
Venture Round in 2013
SynapDx is a diagnostic company based in Lexington, Massachusetts, focused on providing laboratory testing services aimed at the early detection of autism spectrum disorders (ASDs) in children. Established by Stanley Lapidus, the company develops blood-based diagnostic tests that leverage insights from experts in ASD and gene expression. These tests are designed to assist healthcare providers in identifying early symptoms of autism, addressing the need for timely intervention in a condition that affects approximately 1 in 110 children in the United States. Through its innovative approach, SynapDx aims to enhance the diagnostic process for developmental disorders and improve outcomes for affected children and their families.
Flatiron Health
Series A in 2013
Flatiron Health, Inc. is a healthcare technology company dedicated to enhancing cancer research and patient care through advanced data integration and analytics. The firm develops OncologyCloud, a comprehensive platform that consolidates disparate healthcare information systems to provide insights into patient populations. This platform enables cancer care providers and life sciences companies to analyze treatment patterns, monitor adherence to clinical guidelines, and facilitate real-time patient matching to clinical trials. Additionally, Flatiron offers OncoCloud, a software solution for community oncology practices, and tools like Flatiron Assist and OncoEMR, which support clinical decision-making and compliance with oncology care models. Established in 2012 and headquartered in New York, Flatiron Health collaborates with over 280 community cancer practices, prominent academic research centers, and leading oncology companies, positioning itself as a key player in the oncology data landscape. The company operates as a subsidiary of Roche Holding AG.
Predilytics
Series A in 2012
Predilytics, Inc. is a healthcare information technology company that specializes in providing analytic solutions for health plans, providers, and other risk-bearing entities. Founded in 2011 and headquartered in Burlington, Massachusetts, Predilytics harnesses machine-learning tools to analyze both structured and unstructured data, integrating external data sources to generate actionable insights. The company offers a range of solutions aimed at improving healthcare outcomes, including Consumer Acquisition and Retention solutions, which help organizations understand consumer behavior for better product design; Care Directions solutions, targeting high-risk members for effective care management; Risk Adjustment solutions, enhancing reimbursement accuracy and quality of care; and Quality Insight solutions, which identify performance gaps to drive improvements. By focusing on predictive analytics, Predilytics enables healthcare organizations to optimize care delivery, control costs, and improve population health.
DNAnexus, Inc. is a cloud-based provider of genome informatics and data management tools, primarily serving enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and the integration of genomic data with clinical information. Its suite of products includes MOSAIC Microbiome for collaborative research on the human microbiome, DNAnexus Apollo for clinico-genomic data exploration, and DNAnexus Titan for data analysis. Additionally, the DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration, while the Clinico-Genomic Data Solution addresses the need for disease-specific datasets through partnerships with healthcare providers. The company has established itself as a key player in the biopharmaceutical, diagnostic, and academic research sectors, enabling clients to tackle complex challenges in human health with enhanced security and scalability. DNAnexus also maintains a strategic alliance with WuXi NextCODE Genomics and has locations in San Francisco, London, and Prague.
Navigenics
Venture Round in 2007
Navigenics, Inc. specializes in personalized genetics testing and health counseling services aimed at educating individuals and their physicians about genetic predispositions. The company provides genetic information and analysis to empower clients to take proactive measures to prevent disease, facilitate early diagnosis, and effectively manage health conditions. Navigenics delivers its services through a network of medical centers and physicians, as well as employer wellness programs at leading corporations. By motivating individuals to act on their genetic insights, Navigenics seeks to enhance overall health outcomes and reduce the impact of potential diseases.
Sprinter Health is a mobile healthcare company that provides on-demand services by sending full-time nurses and phlebotomists to patients' homes. The company aims to improve access to preventive care through modern house calls, enhancing the patient experience and satisfaction. By utilizing a cost-effective hybrid care model, Sprinter Health connects patients with essential healthcare services, allowing them to receive quality care in the comfort of their own homes. This approach not only improves health outcomes but also addresses the growing demand for convenient and accessible healthcare solutions.